Search results
Showing 8041 to 8055 of 8973 results
Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]
Discontinued Reference number: GID-TA11257
Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]
Discontinued Reference number: GID-TA11262
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
In development Reference number: GID-TA11272 Expected publication date: TBC
In development Reference number: GID-TA11274 Expected publication date: TBC
Multiple sclerosis (primary-progressive) - fingolimod [ID62]
Discontinued Reference number: GID-TAG221
Discontinued Reference number: GID-TA11204
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]
Discontinued Reference number: GID-TA10869
In development Reference number: GID-TA10607 Expected publication date: TBC
Discontinued Reference number: GID-SGWAVE0701
Discontinued Reference number: GID-SGWAVE0761
In development Reference number: GID-TA11443 Expected publication date: TBC
In development Reference number: GID-TA11301 Expected publication date: TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Discontinued Reference number: GID-TA11442
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.